Startup Funding Instruments by Stage in India

Introduction

Fundraising in India has moved far beyond term sheets and valuations—it is now about structuring capital in a way that aligns with growth uncertainty, regulatory boundaries, and investor comfort. Early-stage founders often default to whatever instrument is “trending,” but the reality is more nuanced: the choice between SAFE, CCD, CCPS, and iSAFE can materially influence dilution, compliance burden, and negotiation dynamics.

This article breaks down how each instrument fits into different funding stages in India, with a practical, ground-level perspective.

Decoding the Instruments

SAFE (Simple Agreement for Future Equity)
SAFE is a contractual right to receive equity upon a future financing event. It avoids immediate valuation discussions and keeps documentation light. However, in India, enforceability and regulatory clarity remain areas of caution, especially where foreign investors are involved.

iSAFE (Indianized SAFE)
iSAFE is a localized adaptation of SAFE, structured to align better with Indian company law and tax considerations. It attempts to replicate the flexibility of SAFE while addressing concerns around enforceability and regulatory compliance.

CCD (Compulsorily Convertible Debentures)
CCD is a hybrid instrument—initially structured as debt but mandatorily convertible into equity at a future date. It is widely used in India, especially where valuation clarity is evolving but investor downside protection is required.

CCPS (Compulsorily Convertible Preference Shares)
CCPS are equity-linked instruments with preferential rights such as liquidation preference, anti-dilution protection, and dividend rights. They are the most commonly used instruments in institutional rounds in India.

Stage-Wise Suitability of Instruments

1. Idea / Pre-Seed Stage

At this stage, uncertainty is highest—valuation is subjective, and speed is critical.

• Best Fit: SAFE / iSAFE 
• Why: 
  • Minimal documentation 
  • No immediate valuation pressure 
  • Faster closure with angel investors 

That said, pure SAFE structures can face legal ambiguity in India. iSAFE is often preferred as it provides a more structured and locally adapted approach.

2. Seed Stage

Startups begin demonstrating early traction but still lack stable financial metrics.

• Best Fit: iSAFE / CCD 
• Why: 
  • iSAFE continues to offer flexibility 
  • CCD introduces structured conversion with downside protection 

Investors at this stage start negotiating valuation caps and discounts more aggressively. CCDs become attractive where investors want clarity on conversion mechanics.

3. Early Growth (Pre-Series A / Series A)

Here, valuation discussions become more data-driven, and institutional investors enter the cap table.

• Best Fit: CCPS 
• Why: 
  • Clearly defined valuation 
  • Investor rights (liquidation preference, anti-dilution) 
  • Alignment with venture capital norms 

At this stage, using SAFEs becomes less common as investors demand stronger governance rights.

4. Growth / Expansion Stage (Series B and beyond)

Startups now have established metrics and require structured capital.

• Best Fit: CCPS (dominant), occasionally CCD 
• Why: 
  • Institutional comfort 
  • Detailed shareholder agreements 
  • Governance and exit clarity 

CCDs may still be used in structured deals or bridge rounds, especially where timing mismatches exist.

Key Decision Drivers

Instead of focusing only on the instrument, founders should evaluate:

• Valuation certainty vs. flexibility 
• Speed of execution vs. legal robustness 
• Investor profile (angel vs. institutional) 
• Regulatory considerations (especially FEMA for foreign investors) 
• Future fundraising implications 

For instance, excessive reliance on SAFEs early on can create cap table complexity during conversion, while premature use of CCPS may lead to over-negotiation at a fragile stage.

Common Pitfalls in the Indian Context

1. Blindly adopting Silicon Valley structures without adapting to Indian law 

2. Ignoring tax implications, especially around conversion pricing 

3. Overusing hybrid instruments, leading to complicated cap tables 

4. Underestimating investor expectations at later stages 

Conclusion

There is no universally “best” instrument—only contextually appropriate ones. SAFE and iSAFE work well in the early chaos of startup formation, CCD bridges uncertainty with structure, and CCPS becomes indispensable as institutional capital steps in.

The real skill lies not in choosing the trendiest instrument, but in aligning the funding structure with the startup’s maturity, regulatory environment, and long-term dilution strategy.